Conducts and supports research on the prevention and early detection of prostate and bladder cancers. Develops and supports prevention trials and evaluation of new agents, surrogate biomarkers, and emerging technologies for identifying premalignant lesions.
On This Page
- All Heading 2s will automatically be pulled in to this list.
- Do not edit the content on this template.
Major Programs
Staff List
| Photo | Name, Email, Phone | Room | Group(s)/Office |
|---|---|---|---|
 |
Asefa, Mela mela.asefa@nih.gov 240-276-6422 |
5E328 | Program Support Assistant
|
Breast and Gynecologic Cancer
Program Support Assistant | Prostate and Urologic Cancer |
 |
House, Margaret, RN, B.S.N. margaret.house@nih.gov 240-276-7047 |
5E306 | Deputy Chief | Prostate and Urologic Cancer |
 |
Parnes, Howard L., M.D. howard.parnes@nih.gov 240-276-7045 |
5E302 | Chief | Prostate and Urologic Cancer |
Grants
| PI Name Sort descending | PI Organization | Title | Grant Number | Program Official |
|---|---|---|---|---|
| Cohn, Barbara A | Public Health Institute |
Discriminatory Mechanisms in Early-Onset and Lethal Prostate Cancer | 5R01CA264519-05 | Howard L. Parnes, M.D. |
| Czerniak, Bogdan A | University Of Tx Md Anderson Can Ctr |
Mechanisms of Bladder Cancer Development and Its Therapeutic Vulnerabilities to Preventive and Interventive Therapy. | 1P01CA296429-01A1 | Howard L. Parnes, M.D. |
| Kim, Hyung L | Cedars-Sinai Medical Center |
Intensive cholesterol-lowering intervention and anti-tumor immunity modeled in prostate cancer | 5R01CA280060-03 | Howard L. Parnes, M.D. |
| Kumar, Nagi B. | H. Lee Moffitt Cancer Ctr & Res Inst |
Phase II Clinical trial of GTC in Men on Active Surveillance | 5R01CA235032-06 | Howard L. Parnes, M.D. |
| Svatek, Robert Scott | University Of Texas Hlth Science Center |
eRapa for bladder cancer prevention | 5R01CA252057-05 | Howard L. Parnes, M.D. |